1. Effect of RNAi therapeutics patisiran and vutrisiran on orthostatic hypotension due to dysautonomia in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. (3rd October 2022) Authors: Slama, M; Obici, L; Okumura, T; Arum, S; Hale, C; Jay, P Y; Capocelli, K; Gonzalez-Duarte, A Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effect of the cold pressor test on coronary flow reserve by cardiac magnetic resonance in patients with hereditary TTR+ amyloidosis. (3rd October 2022) Authors: Chango, D X; Hurtado, A M; Sanchez, M I; Vasquez, Z Y; Gonzalez-Duarte, A; Rosales, S Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Long-term integrated safety of patisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. (25th November 2020) Authors: Gillmore, J; Berk, J; Dispenzieri, A; Polydefkis, M; Gonzalez-Duarte, A; Sekijima, Y; Sweetser, M.T; Arum, S; Wang, J.J; White, M.T; Maurer, M Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P.024 Long-term use of patisiran in patients with hereditary transthyretin amyloidosis (hATTR): 12 month efficacy & safety data from a global open label extension (OLE) study. (5th June 2019) Authors: Gonzalez-Duarte, A; Coelho, T; Adams, D; Yang, C; Polydefkis, M; Kristen, A; Tournev, I; Schmidt, H; Berk, J; Lin, K; Gandhi, PJ; Sweetser, M; White, M; Gollob, J; Suhr, OB Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P.024 Long-term use of patisiran in patients with hereditary transthyretin amyloidosis (hATTR): 12 month efficacy & safety data from a global open label extension (OLE) study. (June 2019) Authors: Gonzalez-Duarte, A; Coelho, T; Adams, D; Yang, C; Polydefkis, M; Kristen, A; Tournev, I; Schmidt, H; Berk, J; Lin, K; Gandhi, PJ; Sweetser, M; White, M; Gollob, J; Suhr, OB Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P.025 APOLLO, a phase 3 study of patisiran for the treatment of hereditary transthyretin amyloidosis (hATTR): 18-month safety and efficacy in subgroup with cardiac involvement. (5th June 2019) Authors: Vest, J; Solomon, S; Adams, D; Gonzalez-Duarte, A; O'Riordan, W; Yang, C; Coelho, T; Berk, J; Lin, K; Dyck, P; Gandhi, PJ; Sweetser, M; Suhr, OB; Kristen, A Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P.025 APOLLO, a phase 3 study of patisiran for the treatment of hereditary transthyretin amyloidosis (hATTR): 18-month safety and efficacy in subgroup with cardiac involvement. (June 2019) Authors: Vest, J; Solomon, S; Adams, D; Gonzalez-Duarte, A; O'Riordan, W; Yang, C; Coelho, T; Berk, J; Lin, K; Dyck, P; Gandhi, PJ; Sweetser, M; Suhr, OB; Kristen, A Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗